Navigation Links
Cardium Provides Update on Phase 2b Excellarate Clinical Study and Plans for Additional Tissue Repair Applications
Date:7/28/2009

SAN DIEGO, Calif., July 28 /PRNewswire-FirstCall/ -- Cardium Therapeutics (NYSE Amex: CXM) and its subsidiary Tissue Repair Company (TRC) today provided an update on the completion of their MATRIX Phase 2b clinical study and announced plans to provide detailed safety and efficacy data for their Excellarate(TM) product candidate around the end of September. The MATRIX trial, a prospective, randomized, double-blind, placebo-controlled study, has enrolled 124 diabetic patients with non-healing, lower extremity neuropathic ulcers.

(Logo: http://www.newscom.com/cgi-bin/prnh/20051018/CARDIUMLOGO)

The companies also reported that results from the MATRIX clinical study are expected to be used to support additional studies and applications of Tissue Repair's Gene Activated Matrix(TM) or GAM(TM) technology for ulcers and other potential applications, including not only the repair of soft tissue injuries such as diabetic or pressure ulcers, but hard tissue injuries such as those affecting bone. Additional information regarding the use of Excellarate for the potential treatment of diabetic foot ulcers and other potential GAM product candidates is expected to be reported over the next several weeks and months.

"We are pleased to report that more than 90% of the patients enrolled into the MATRIX study have now completed their initial 12-week evaluation period with respect to key safety and efficacy criteria. While the efficacy data from the MATRIX study remains blinded as final patients advance through the 12-week evaluation period, there continues to be no safety concerns since our announcement of completion of patient recruitment in May 2009. We are also excited to be completing data collection and re
'/>"/>

SOURCE Cardium Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. Cardium Regains Listing Compliance with NYSE Amex
2. Cardiums InnerCool Therapies Business to Be Acquired By Royal Philips Electronics
3. Cardium Announces Conference Call and Webcast to Review Recent Developments and Future Plans for the Excellarate(TM) Clinical Development Program
4. FDA has Granted HUD (Humanitarian Use Device) Designation to ITGIs Pericardium Covered Stents, Over and Under(R) and Aneugraft(R), for Treatment of Perforations and Dissections of Native Coronary Arteries and Saphenous Vein Grafts
5. Cardium Completes $3.5 Million Credit Facility
6. Cardium Announces Retirement of Director
7. Cardiums InnerCool Announces First Patient Treated With New Tissue-Specific UroCool(TM) System in Robotic-Assisted Prostate Surgery Study
8. Cardiums InnerCool Announces New Tissue-Specific UroCool(TM) System for Use in Prostate Surgeries
9. Cardium Reports on Third Quarter 2008 Financial Results and Revised Business Strategies for Operating Units
10. Cardium Announces FDA 510(K) Clearance of InnerCools RapidBlue(TM) Endovascular System
11. ITGI Medical Received a CE Mark for its Second Pericardium Covered Stent - AneuGraft(R) - for Tortuous Vessels

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)..., NEW YORK, Nov. 25 Reportlinker...s available in its catalogue: ,, Brazil Bioeth... http://www.reportlinker.com/p0165503/Brazil-Bioet...,, Brazil Bioethanol Market Analysis and Foreca...des detailed analysis and forecasts of the global ...
(Date:11/24/2009)...e is available in German . , Whether it,s C...FID tags (Radio Frequency Identification) are incr...y make it possible to label objects or goods and i... appropriate scanner can read and process the data...ed to goods under production conditions of up to 1...
(Date:11/24/2009)... Ambassador to also Visit Detroit , ... , , ,Who: David Appia, French Ambassador for Inte...Invest in France Agency, , , , ,What: Ambassador ...ecent pro-business initiatives adopted by France t...ic landscape for innovation and development., , ,W...
(Date:11/24/2009)..., SANTA CRUZ, Calif., Nov. 24 Two ...er Center, the nation,s leading online job board a..., Northwestern and Columbia University are now m...fe science training Institutions. ,, The job bo...raduates in the life sciences. While there are hun...
Breaking Biology Technology:Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 2Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 3Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 4Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 5Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 6Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 7Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 8Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 9Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 10Intelligence inside metal components 2Two Major Universities Join Nation's Leading Postgrad Bio Job Board 2
...s most widely used drugs, is also one of the trick...t risk of serious problems when given the standard...rations of "personalized medicine" based on geneti...created a model to help doctors determine the best... , Three University of Wisconsin-Madison researc...
...N, Mass., Feb. 18 Psychemedics Corporation (Nasda...-end financial results for the period ended Decemb...ly dividend of $0.17 per share payable to sharehol...arch 20, 2009. This will be the Company,s 50th co...evenue for the year ended December 31, 2008 was $2...
...ary 18 ,Amsterdam Molecular Therapeutics (Euronext...y, announced today that it will release its financ...ruary 24, 2009 at 7:00 am,Central European Time (C...nduct a conference call that day at 3 p.m. CET. , ...-949-4166 (toll free). The,number for Germany is 0...
Other Biology Technology:Genetic information personalizes warfarin prescribing 2Genetic information personalizes warfarin prescribing 3Psychemedics Corporation Announces 2008 Year End Results 2Psychemedics Corporation Announces 2008 Year End Results 3Psychemedics Corporation Announces 2008 Year End Results 4Psychemedics Corporation Announces 2008 Year End Results 5AMT to Release Full Year 2008 Results on February 24, 2009 2
(Date:11/30/2009)...ght the stress of seeing your extended family over...w research report in the December 2009 print issue...w.jleukbio.org ) shows that you might be right. He...ght lead to entirely new treatments that help keep...zema under control. That,s because researchers fro...
(Date:11/26/2009)...s are some of the Ocean,s most distinctive residen...is strange head shape, says Michelle McComb from ...s the shark,s vision. ,Perhaps their visual field ... McComb, giving the sharks excellent stereovision ..., there were two schools of thought on this theory...
(Date:11/26/2009)... (November 26, 2009) Whitehead researchers have d...lls to pinpoint specific genes and proteins used b.... , In most human cell cultures genes are presen... one from the mother. Gene inactivation by mutatio...s inactivated, the second copy usually remains act...
Breaking Biology News(10 mins):Seeing family for the holidays? Scientists discover how the stress might kill you 2Wide heads give hammerheads exceptional stereo view 2Knockouts in human cells point to pathogenic targets 2New Results From ARTEN Study of Nevirapine Plus Tenofovir and Emtricitabine 28TDF FTC 29 Versus Boosted Protease Inhibitor Regimen of Atazanavir Rito 4747 1New Results From ARTEN Study of Nevirapine Plus Tenofovir and Emtricitabine 28TDF FTC 29 Versus Boosted Protease Inhibitor Regimen of Atazanavir Rito 4747 2New Results From ARTEN Study of Nevirapine Plus Tenofovir and Emtricitabine 28TDF FTC 29 Versus Boosted Protease Inhibitor Regimen of Atazanavir Rito 4747 3New Results From ARTEN Study of Nevirapine Plus Tenofovir and Emtricitabine 28TDF FTC 29 Versus Boosted Protease Inhibitor Regimen of Atazanavir Rito 4747 4New Results From ARTEN Study of Nevirapine Plus Tenofovir and Emtricitabine 28TDF FTC 29 Versus Boosted Protease Inhibitor Regimen of Atazanavir Rito 4747 5New Results From ARTEN Study of Nevirapine Plus Tenofovir and Emtricitabine 28TDF FTC 29 Versus Boosted Protease Inhibitor Regimen of Atazanavir Rito 4747 6Perception May Affect Drinking by College Students 52095 1Perception May Affect Drinking by College Students 52095 2Exposure to Common Pollutant in Womb Might Lower IQ 52093 1Exposure to Common Pollutant in Womb Might Lower IQ 52093 2Exposure to Common Pollutant in Womb Might Lower IQ 52093 3
...e can be increased by eating a higher protein diet... journal Cell Metabolism, published by Cell Press....er found by the researchers to reduce food intake ...when given by injection. , "We,ve now found that ...s the body,s own PYY, helping to reduce hunger and...
...r, healthier lives since the development of highly... In fact, most patients on the drug regimen do so ...cells appear to return to pre-HIV levels. But two ...ron Diamond AIDS Research Center (ADARC) show that...rebound, suggesting the need for additional ways t...
... that vaccinating mice with embryonic stem cells p... cancer cells transplanted into them after the vac...g chemicals. , The findings suggest that it coul...nes that prevent cancers in humans, such as heredi...d by smoking or other environmental factors. ,...
Other Biology News:Eating protein boosts hormone that staves off hunger 2HIV-1 kills immune cells in the gut that may never bounce back 2HIV-1 kills immune cells in the gut that may never bounce back 3Vaccination with embryonic stem cells prevents lung cancer in mice 2Vaccination with embryonic stem cells prevents lung cancer in mice 3
GeneRacer Kit with AMV RT and TOPO TA Cloning kit for Sequencing from Invitrogen
Chloride Colorimetric Assay Kit, QuantiChrom from BioAssay Systems
Phosphate Colorimetric Assay Kit from BioAssay Systems
QuantiChrom Magnesium Assay Kit from BioAssay Systems
Biology Products: